Comparison of NN1250 with insulin glargine in type 2 diabetes
- Conditions
- Health Condition 1: E08-E13- Diabetes mellitusHealth Condition 2: null- Diabetes Mellitus, Type 2
- Registration Number
- CTRI/2009/091/000804
- Lead Sponsor
- ovo Nordisk AS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 687
Type 2 diabetes mellitus for at least 6 months
Currently treated with oral antidiabetic drugs, treated with insulin or a combination of oral antidiabetic drugs and insulin for at least 3 months
For patients currently treated with oral antidiabetic drug: HbA1c 7-11%
For patients currently treated with insulin: HbA1c 7-10%
Body Mass Index (BMI) below or equal to 40.0 kg/m2
Age 18 years and older
Use GLP-1 receptor agonist (exenatide, liraglutide), rosiglitazone, DPP-IV inhibitors, a-glucosidase-inhibitors within the last 3 months prior to trial start
Cardiovascular disease, within the last 6 months
Uncontrolled treated/untreated severe hypertension
Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures
Cancer and medical history of cancer hereof
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method